My Account
About Us
Contact us
الواجهة العربية
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



You must sign in to use this servcie

Feedback - Please use the form below to send your query or comment

You must sign in to use this servcie




Dextromethorphan hydrobromide is a cough suppressant used for the relief of non-productive cough Bromhexine hydrochloride indicated for cough associated with wheeziness (bronchospasm) and tenacious phlegm (sputum).


Dextromethorphan should not be given to patients at risk of developing respiratory failure. Caution is needed in patients with a history of asthma and it should not be given during an acute attack. Bromhexine hydrochloride SYRUP is contra-indicated in patients with known hypersensitivity to sympathomimetic amines or any of the other ingredients; hypertrophic obstructive cardiomyopathy; and tachyarrhythmia. Sympathomimetics, such as orciprenaline sulphate, may interact with monoamine oxidase inhibitors (MAOI), and therefore Bromhexine hydrochloride SYRUP should not be given to patients receiving such treatment or within 14 days of MAOI treatment termination. Safety in pregnancy and lactation has not been established.

Adverse reactions:

Adverse effects with dextromethorphan appear to be rare and may include dizziness and gastrointestinal disturbances. Excitation, confusion, and respiratory depression may occur after overdosage. Dextromethorphan has been subject to abuse, but there is little evidence of dependence of the morphine type. Bromhexine’s pharmacological action may lead to gastric irritation. A transient rise in serum aminotransferase values have been reported due to bromhexine. Orciprenaline sulphate, as a sympathomimetic agent, may precipitate a wide range of adverse effects. Side-effects include fear; anxiety, restlessness, tremor , insomnia, confusion, irritability, weakness and psychotic states. Appetite may be reduced and nausea and vomiting may occur. A rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, tachycardia and cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest. Hypotension with dizziness and fainting and flushing may occur. Other effects that may occur include difficulty in micturition and urinary retention; dyspnoea; weakness; headache; disturbances of glucose metabolism; sweating and hypersalivation. Muscle cramps or twitching or unpleasant taste may occur.


Severe and sometimes fatal reactions have been reported after use of dextromethorphan in patients receiving MAOIs. Dextromethorphan is primarily metabolised by the cytochrome P450 isoenzyme CYP2D6; the possibility of interactions with inhibitors of this enzyme, including amiodarone, fluoxetine, haloperidol, paroxetine, propafenone, quinidine, and thioridazine, should be borne in mind. A reduction in dose of cardiac glycosides (e.g. digitalis) and quinidine might become necessary in patients suffering from congestive cardiac failure because of the positive inotropic effect of orciprenaline sulphate. Bromhexine hydrochloride SYRUP should not be administered concomitantly with beta-blocking agents, due to orciprenaline’s reversal of anti-hypertensive action. The concomitant use of other sympathomimetic agents should be carefully controlled to avoid potentiation of effects.


Bromhexine hydrochloride should be avoided or used with caution in patients undergoing anaesthesia with cyclopropane, halothane or other halogenated anaesthetics, as it may induce ventricular fibrillation. An increased risk of arrhythmias may also occur if given to patients receiving cardiac glycosides, quinidine or tricyclic antidepressants. Hypokalaemia may be induced by higher than recommended doses of beta-agonists, especially in patients receiving digitalis glycosides or diuretics or are prone to cardiac dysrrhythmias. Caution should be exercised in patients suffering from hyperthyroidism due to sympathomimetic effects of orciprenaline sulphate. Caution should be observed in patients with gastric ulcer due to the bromhexine hydrochloride mucolytic action. In addition, care should be observed in patients suffering from cardiovascular diseases i.e. ischaemic heart disease; arrhythmias or tachycardia; occlusive vascular disorders including arteriosclerosis, hypertension or aneurysms. Anginal pain may be precipitated in patients suffering from angina pectoris. Care is also required when Bromhexine hydrochloride SYRUP is given to patients with diabetes mellitus or closed angle glaucoma. Caution is also needed in patients with convulsive disorders.



Dosage and Administration

You must sign in to use this servcie

Technical Description

You must sign in to use this servcie

Forgot your password

sign up

Consultants Corner

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr. Talal Sabouni


Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details